Results 71 to 80 of about 98,806 (295)
Role of Enlarged Perivascular Space in the Temporal Lobe in Cerebral Amyloidosis
, 2023 Han Kyu Na +7 more
openalex +2 more sources
Amyloidosis and neurological disorders: Treatable amyloidosis
Rinsho Shinkeigaku, 2015 In neurological disorder related amyloidosis, several therapies have been developed in the recent decade. In AL and AA amyloidosis, novel chemotherapy and IL6 receptor antibody have been found to be effective, respectively. In addition to these amyloidosis, in transthyretin (TTR) related familial amyloidotic polyneuropathy (FAP), liver transplantation,
openaire +3 more sources
ESC Heart Failure, EarlyView.Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra +25 more
wiley +1 more source
Aβ Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model [PDF]
, 2010 David Hurtado +6 more
openalex +1 more source
Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction [PDF]
, 2023 Joshua Saef +9 more
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal +9 more
wiley +1 more source
Parkinson’s disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein [PDF]
, 2019 Katsuya Araki +8 more
openalex +1 more source
ESC Heart Failure, EarlyView.The aim of our study was to develop a more accurate staging system for hereditary ATTR patients currently receiving specific treatment. A staging system was created using as criteria: GLS ≤ −11%, NT‐proBNP ≤ 2,000 ng/L, and eGFR ≤ 65 mL/min. We managed to accurately stratify patients into three disease stages, significantly different in terms of ...
Gabriela Neculae +7 more
wiley +1 more source
European Respiratory Review, 2017 Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary
Paolo Milani +5 more
doaj +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single‐photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM ...
Pablo Garcia‐Pavia +11 more
wiley +1 more source